Guanzhao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guanzhao Wu has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Liying Meng
11 shared publicationsMei Li
7 shared publicationsZetai Bai
7 shared publicationsZheyi Wang
7 shared publicationsDeyuan Kong
Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerative Diseases, Qilu Hospital of Shandong University, Jinan, Shandong, China; Qingdao Key Laboratory of Mitochondrial Medicine, Qilu Hospital (Qingdao), Shandong University, Qingdao, Shandong 266035, China
5 shared publicationsXuemeng Liu
Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong 266035, China; Qingdao Key Lab of Mitochondrial Medicine, Qilu Hospital (Qingdao), Shandong University, Qingdao 266035, Shandong, China
4 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (7) , e71601
Impact of Physical Activity on Stroke Risk in Middle‐Aged and Older Adults
Purpose: The relationship between physical activity intensity and the risk of first‐ever stroke in middle‐aged and older adults remains incompletely understood. This study aimed to investigate the association between different intensities and total volumes of physical activity and the incidence of first stroke, and to explore potential cardiovascular mediators underlying this relationship. Method: This prospective cohort study utilized data from the China Health and Retirement Longitudinal Study (CHARLS), including 4380 stroke‐free adults aged ≥ 45 years at baseline. Physical activity was assessed using the International Physical Activity Questionnaire Short Form and classified into sedentary behavior, active physical activity, and highly active physical activity. Total physical activity was quantified in metabolic equivalent task minutes per week (MET‐min/week). Incident stroke was identified through self‐reported physician diagnosis during a 7‐year follow‐up period. Cox proportional hazards models, multivariable logistic regression, restricted cubic spline analyses, subgroup analyses, and mediation analyses were conducted after adjusting for demographic, lifestyle, and clinical confounders. Finding: During follow‐up, 300 participants (6.8%) experienced a first‐ever stroke. Highly active physical activity was associated with a significantly reduced risk of first stroke compared with sedentary behavior (adjusted hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.30–0.92; adjusted odds ratio [OR], 0.45; 95% CI, 0.36–0.55). A nonlinear, flipped J ‐shaped dose–response relationship was observed between total physical activity and stroke risk, with the lowest risk occurring at approximately 13,045 MET‐min/week. Subgroup analyses showed stronger protective effects of highly active physical activity in men, individuals without heart disease, overweight individuals, and those with hypertension. Mediation analyses indicated that the protective association was largely mediated by improvements in cardiovascular indicators, including blood pressure, high‐density lipoprotein cholesterol, body mass index, and the triglyceride–glucose index. Conclusion: The inverse association between highly active physical activity and first stroke was partially accounted for by cardiovascular biomarkers.
- 14 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (7) , e71601
Open AccessImpact of Physical Activity on Stroke Risk in Middle‐Aged and Older Adults
Purpose: The relationship between physical activity intensity and the risk of first‐ever stroke in middle‐aged and older adults remains incompletely understood. This study aimed to investigate the association between different intensities and total volumes of physical activity and the incidence of first stroke, and to explore potential cardiovascular mediators underlying this relationship. Method: This prospective cohort study utilized data from the China Health and Retirement Longitudinal Study (CHARLS), including 4380 stroke‐free adults aged ≥ 45 years at baseline. Physical activity was assessed using the International Physical Activity Questionnaire Short Form and classified into sedentary behavior, active physical activity, and highly active physical activity. Total physical activity was quantified in metabolic equivalent task minutes per week (MET‐min/week). Incident stroke was identified through self‐reported physician diagnosis during a 7‐year follow‐up period. Cox proportional hazards models, multivariable logistic regression, restricted cubic spline analyses, subgroup analyses, and mediation analyses were conducted after adjusting for demographic, lifestyle, and clinical confounders. Finding: During follow‐up, 300 participants (6.8%) experienced a first‐ever stroke. Highly active physical activity was associated with a significantly reduced risk of first stroke compared with sedentary behavior (adjusted hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.30–0.92; adjusted odds ratio [OR], 0.45; 95% CI, 0.36–0.55). A nonlinear, flipped J ‐shaped dose–response relationship was observed between total physical activity and stroke risk, with the lowest risk occurring at approximately 13,045 MET‐min/week. Subgroup analyses showed stronger protective effects of highly active physical activity in men, individuals without heart disease, overweight individuals, and those with hypertension. Mediation analyses indicated that the protective association was largely mediated by improvements in cardiovascular indicators, including blood pressure, high‐density lipoprotein cholesterol, body mass index, and the triglyceride–glucose index. Conclusion: The inverse association between highly active physical activity and first stroke was partially accounted for by cardiovascular biomarkers.
- 9 July 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 141, 118750
Discovery of a mitochondria-targeted propranolol conjugate PL37 that induces mitophagy for potent anti-hemangioma activity
- 9 July 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 141, 118750
Discovery of a mitochondria-targeted propranolol conjugate PL37 that induces mitophagy for potent anti-hemangioma activity
- 7 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (8) , 9713-9731
Discovery of Imidazo[2,1- b ][1,3,4]thiadiazole-Based MNK Inhibitors with Anti-inflammatory Efficacy via Dual Suppression of eIF4E Phosphorylation and NF-κB Signaling
Mitogen-activated protein kinase-interacting kinase (MNK), a pivotal kinase downstream of MAPK signaling, is currently the only enzyme reported to be capable of phosphorylating eIF4E. This study first confirmed that MNK silencing in LPS-stimulated macrophages inhibits eIF4E phosphorylation, inflammatory polarization, and cytokine release. Based on the prior discovery that the imidazo[2,1-b][1,3,4]thiadiazole skeleton can effectively inhibit the MNK kinases, this study further designed and synthesized a series of imidazo[2,1-b][1,3,4]thiadiazole derivatives modified with sulfonyl or phosphoryl groups. Among these derivatives, compound 13 potently and selectively inhibited MNK1/2 (IC50 = 10.84/12.81 nM), exerted dose-dependent anti-inflammatory effects in LPS-induced RAW 264.7 cells, and alleviated kidney and spleen damage in the mouse model of LPS-induced inflammation. Mechanistically, 13 suppressed eIF4E phosphorylation, NF-κB signaling, and macrophage polarization, thereby reducing pro-inflammatory cytokines and oxidative stress. These results suggest that MNK inhibition is a promising strategy for treating inflammatory diseases by targeting both inflammation and oxidative stress.
- 7 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (8) , 9713-9731
Discovery of Imidazo[2,1- b ][1,3,4]thiadiazole-Based MNK Inhibitors with Anti-inflammatory Efficacy via Dual Suppression of eIF4E Phosphorylation and NF-κB Signaling
Mitogen-activated protein kinase-interacting kinase (MNK), a pivotal kinase downstream of MAPK signaling, is currently the only enzyme reported to be capable of phosphorylating eIF4E. This study first confirmed that MNK silencing in LPS-stimulated macrophages inhibits eIF4E phosphorylation, inflammatory polarization, and cytokine release. Based on the prior discovery that the imidazo[2,1-b][1,3,4]thiadiazole skeleton can effectively inhibit the MNK kinases, this study further designed and synthesized a series of imidazo[2,1-b][1,3,4]thiadiazole derivatives modified with sulfonyl or phosphoryl groups. Among these derivatives, compound 13 potently and selectively inhibited MNK1/2 (IC50 = 10.84/12.81 nM), exerted dose-dependent anti-inflammatory effects in LPS-induced RAW 264.7 cells, and alleviated kidney and spleen damage in the mouse model of LPS-induced inflammation. Mechanistically, 13 suppressed eIF4E phosphorylation, NF-κB signaling, and macrophage polarization, thereby reducing pro-inflammatory cytokines and oxidative stress. These results suggest that MNK inhibition is a promising strategy for treating inflammatory diseases by targeting both inflammation and oxidative stress.
- 31 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7856-7868
Design, Synthesis, and Structure–Activity Relationship Study of μ-Conotoxin KIIIA toward Na V 1.4
NaV1.4 expressed in skeletal muscle, is a validated target for treating neuromuscular disorders. While the μ-conotoxin KIIIA is the one of the smallest conopeptide inhibitors of NaV1.4, its therapeutic potential is limited by potency and synthetic complexity. Using a computational model, we designed analogues with added positive charges, yielding [K7R, A15R]KIIIA-1 (IC50 = 20.5 nM). Further optimization produced [S5R]KA with high potency (IC50 = 5.1 nM) but poor enzymatic stability (t1/2 < 4 h). To improve stability, we replaced Cys4 with penicillamine (Pen), generating C4Pen. This analogue maintained excellent activity (IC50 = 11.1 nM) and significantly improved stability (t1/2 > 8 h), and both analogues preferentially inhibited NaV1.4 with moderate activity at NaV1.2 and NaV1.7 and exhibited no detectable inhibition of NaV1.5. In vivo studies confirmed that both [S5R]KA and C4Pen induce potent muscle relaxation. This structure-based optimization combines electrostatic mutagenesis with Pen-mediated stabilization, yielding a promising peptide therapeutic candidate.
- 31 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7856-7868
Design, Synthesis, and Structure–Activity Relationship Study of μ-Conotoxin KIIIA toward Na V 1.4
NaV1.4 expressed in skeletal muscle, is a validated target for treating neuromuscular disorders. While the μ-conotoxin KIIIA is the one of the smallest conopeptide inhibitors of NaV1.4, its therapeutic potential is limited by potency and synthetic complexity. Using a computational model, we designed analogues with added positive charges, yielding [K7R, A15R]KIIIA-1 (IC50 = 20.5 nM). Further optimization produced [S5R]KA with high potency (IC50 = 5.1 nM) but poor enzymatic stability (t1/2 < 4 h). To improve stability, we replaced Cys4 with penicillamine (Pen), generating C4Pen. This analogue maintained excellent activity (IC50 = 11.1 nM) and significantly improved stability (t1/2 > 8 h), and both analogues preferentially inhibited NaV1.4 with moderate activity at NaV1.2 and NaV1.7 and exhibited no detectable inhibition of NaV1.5. In vivo studies confirmed that both [S5R]KA and C4Pen induce potent muscle relaxation. This structure-based optimization combines electrostatic mutagenesis with Pen-mediated stabilization, yielding a promising peptide therapeutic candidate.
- Top Cited PapersOpen Access
- 3 March 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
The lung-brain axis: elucidating the mechanisms of pulmonary-driven neurological disorders
The brain and lungs represent two of the most vital organs in the human body. The conceptualization of the lung-brain axis has advanced our understanding of the bidirectional communication between the respiratory and central nervous systems. Accumulating evidence indicates that pulmonary diseases, including chronic obstructive pulmonary disease, asthma, acute respiratory distress syndrome and infections such as bacterial pneumonia, influenza and Coronavirus Disease 2019, along with airborne environmental exposures, constitute significant risk factors for various neurological disorders. The lung-brain axis is primarily mediated by microbial, immune, neural, metabolic and hormonal pathways. These mechanisms contribute to the disruption of blood-brain barrier integrity, the activation of neuroglial cells and the dysfunction of the cerebrovascular system, ultimately causing neuronal injury and diverse neurological conditions. Environmental factors, notably airborne particulate matter and chemical pollutants, further amplify the crosstalk among these mechanisms, extending the neurological risk. Here, we summarize the current knowledge regarding the association between pulmonary dysfunction and the development and progression of neurodegenerative diseases (such as Alzheimer’s disease and Parkinson’s disease), stroke, anxiety/depression, epilepsy, and migraine. Additionally, potential therapeutic strategies targeting the lung–brain axis are discussed to foster further research in this emerging field. Elucidating the complex interactions within the lung–brain axis will not only deepen our understanding of the shared pathophysiological mechanisms but also open novel avenues for the early diagnosis, prevention, and treatment of related neurological diseases.
- 3 March 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Top Cited PapersOpen AccessThe lung-brain axis: elucidating the mechanisms of pulmonary-driven neurological disorders
The brain and lungs represent two of the most vital organs in the human body. The conceptualization of the lung-brain axis has advanced our understanding of the bidirectional communication between the respiratory and central nervous systems. Accumulating evidence indicates that pulmonary diseases, including chronic obstructive pulmonary disease, asthma, acute respiratory distress syndrome and infections such as bacterial pneumonia, influenza and Coronavirus Disease 2019, along with airborne environmental exposures, constitute significant risk factors for various neurological disorders. The lung-brain axis is primarily mediated by microbial, immune, neural, metabolic and hormonal pathways. These mechanisms contribute to the disruption of blood-brain barrier integrity, the activation of neuroglial cells and the dysfunction of the cerebrovascular system, ultimately causing neuronal injury and diverse neurological conditions. Environmental factors, notably airborne particulate matter and chemical pollutants, further amplify the crosstalk among these mechanisms, extending the neurological risk. Here, we summarize the current knowledge regarding the association between pulmonary dysfunction and the development and progression of neurodegenerative diseases (such as Alzheimer’s disease and Parkinson’s disease), stroke, anxiety/depression, epilepsy, and migraine. Additionally, potential therapeutic strategies targeting the lung–brain axis are discussed to foster further research in this emerging field. Elucidating the complex interactions within the lung–brain axis will not only deepen our understanding of the shared pathophysiological mechanisms but also open novel avenues for the early diagnosis, prevention, and treatment of related neurological diseases.
- 8 December 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 168, 109356
A mitochondria-targeted idebenone derivative W1a mitigates cerebral ischemia-reperfusion injury by preserving mitochondrial integrity and suppressing neuroinflammation
- 8 December 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 168, 109356
A mitochondria-targeted idebenone derivative W1a mitigates cerebral ischemia-reperfusion injury by preserving mitochondrial integrity and suppressing neuroinflammation
- 7 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112221
Idebenone alleviates rotenone-induced mitochondrial dysfunction through mitophagy and mitochondrial biogenesis in muscle cells
- 7 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112221
Idebenone alleviates rotenone-induced mitochondrial dysfunction through mitophagy and mitochondrial biogenesis in muscle cells
- 18 June 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 296, 117873
Discovery of a potential anti-ischemic stroke agent by suppressing ferroptosis through the ATF3/SLC7A11/GPX4 pathway
- 18 June 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 296, 117873
Discovery of a potential anti-ischemic stroke agent by suppressing ferroptosis through the ATF3/SLC7A11/GPX4 pathway